Florian Benoist

This paper demonstrates the use of TfR1-targeting single-domain antibodies to deliver siRNAs systemically to deep brain regions, achieving efficient knockdown at low doses.

This study shows that specific mutations in the C-terminal domains of MT5-MMP reduce C99 and Aβ levels, suggesting a potential therapeutic strategy for Alzheimer's disease.